ArticleBMC cancer2010

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

Steven G Patten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.